Most women aren't told this is treatable. Up to 50% of postmenopausal women develop dryness and discomfort. 40% report a real drop in desire. Both respond to treatment — including the testosterone story you probably haven't heard yet.
US-licensed clinicians · HIPAA-secure
Genitourinary syndrome of menopause (GSM) is the catch-all name for the symptoms you don't see in commercials: dryness, burning, painful sex, more frequent UTIs, and urgency. Up to half of postmenopausal women develop it — and it does not get better on its own.
Separately, but usually overlapping, is the desire problem. Low estrogen blunts arousal. Low testosterone — yes, women have it, and it drops earlier than estrogen — blunts the drive itself. Add in a partner you're snapping at, sleep you're not getting, and pain that makes sex unpleasant, and "I don't want to" becomes a fully rational response, not a defect.
Both pieces are treatable. The local part (dryness, pain) responds almost universally to low-dose vaginal estrogen, one of the safest prescriptions in modern medicine. The desire part often needs testosterone — still routinely underprescribed for women despite strong evidence.
Most women are told the story is "estrogen." That's half right. Sexual function in midlife is a two-hormone problem with a tissue layer underneath.
Without estrogen, vaginal and vulvar tissue loses thickness, blood flow, and natural lubrication. Discomfort is the result.
Vaginal pH rises, lactobacilli decline, and UTIs become more common. This is mechanical, not behavioral.
Ovarian testosterone production drops gradually starting in the late 30s. It's the hormone most directly tied to sexual desire — in women as much as men.
Sleep loss, mood symptoms, and discomfort all blunt desire on top of the hormonal piece. Fix the hormones and the rest often follows.
Pooled outcomes for women receiving low-dose vaginal estrogen + clinician-managed testosterone, vs. baseline.
Mean improvements from pooled RCT and registry data.
Pooled from ACOG and Menopause Society GSM/sexual function guidelines, Davis et al. and Simon et al. RCTs.
Most women don't need to pick just one. Your clinician will build a plan that layers what makes sense for your symptoms, your medical history, and your preferences.
Helpful, but rarely complete on their own. Best paired with medical treatment.
The gold standard for GSM. Local vaginal estrogen barely enters the bloodstream — one of the safest prescriptions in medicine.
Off-label, but endorsed by the Menopause Society and ISSWSH for HSDD. Uses a fraction of the male dose, monitored with labs.
These don't mean treatment is off the table — but they need to be evaluated before starting a hormonal protocol:
Any of these warrants a workup. Our clinicians can review online and either start treatment or recommend the right next step.
Real answers from our clinical team — no fluff, no scare copy, just what you'd want a friend who happened to be a menopause specialist to tell you.